Abstract: The invention relates to processes for purification of poly-tagged products, such as mRNA, from synthetic or biological compositions. The process involves contacting the composition with a oligo d (T)-functionalized chromatography medium comprising a convection-based chromatography material.

Abstract: Methods and systems for preparing ore for precious metal extraction is provided. For example, a method comprises crushing ore; grinding the crushed ore; screening the ground ore to separate ore particles into a first group of large ore particles and a first group of small ore particles; crushing the first group of large ore particles; screening the crushed ore to separate into a second group of large ore particles and a second group of small ore particles; separating the second group of small ore particles from the screen into a third group of large particles and a third group of small particles; milling the third group of large ore particles; separating milled particles into a fourth group of large particles and a fourth group of small particles; and sending the third and fourth group of small particles for further metal extraction processing.

Abstract: An exercise apparatus having a frame with attachments to multiple independent bidirectional resistance devices used by arms and/or legs of a user to provide resistance against movement of the user's appendages in two substantially opposed directions. The resistance devices may have a mechanism to control bi-directional resistance. The movement of the user's appendages in bi-directional resistance offers near full body exercise of agonist/antagonist muscles using flexion and extension action of larger muscle groups in a gait pattern, simultaneously. Hand engaging members attach to arm resistance devices and foot engaging members attach to leg resistance devices. The exercise apparatus may include an attached inclined backboard, mat, bench, or cushion to fully or partially support the user. The exercise apparatus may have separate height and/or length adjustment mechanisms for adjusting a range of motion of the user's appendages.

Abstract: Methods and systems for preparing ore for precious metal extraction is provided. For example, a method comprises crushing ore; grinding the crushed ore; screening the ground ore to separate ore particles into a first group of large ore particles and a first group of small ore particles; crushing the first group of large ore particles; screening the crushed ore to separate into a second group of large ore particles and a second group of small ore particles; separating the second group of small ore particles from the screen into a third group of large particles and a third group of small particles; milling the third group of large ore particles; separating milled particles into a fourth group of large particles and a fourth group of small particles; and sending the third and fourth group of small particles for further metal extraction processing.

Abstract: A rehabilitative and/or exercise machine that has a frame with attachments to multiple independent bidirectional resistance devices (pneumatic, hydraulic, spring actuated, pulley system, cam, or any other resistance devices) used by the arms and/or legs to provide resistance against movement of the user's appendages in two substantially opposed directions. The resistance devices may have a mechanism such as one or more valves, brakes, springs, or the like that control bi-directional resistance. The action of the arms and/or legs in bi-directional resistance offers near full body exercise of the agonist/antagonist muscles using flexion and extension action of the larger muscle groups in a gait pattern, simultaneously. Hand engaging members attach to the arm resistance devices and foot engaging members attach to the leg resistance devices. The unit may include an attached inclined backboard, mat, bench, or cushion to fully or partially support the user, such as for the user to sit or lay on.

Abstract: A rehabilitative and/or exercise machine that has a frame with attachments to multiple independent bidirectional resistance devices (pneumatic, hydraulic, spring actuated, pulley system, cam, or any other resistance devices) used by the arms and/or legs to provide resistance against movement of the user's appendages in two substantially opposed directions. The resistance devices may have a mechanism such as one or more valves, brakes, springs, or the like that control bi-directional resistance. The action of the arms and/or legs in bi-directional resistance offers near full body exercise of the agonist/antagonist muscles using flexion and extension action of the larger muscle groups in a gait pattern, simultaneously. Hand engaging members attach to the arm resistance devices and foot engaging members attach to the leg resistance devices. The unit may include an attached inclined backboard, mat, bench, or cushion to fully or partially support the user, such as for the user to sit or lay on.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.

Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterized by inappropriate expression or activation of cathepsin S.

Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-x; constructs and recombinant host cells incorporating the genes; the nGPCR-x polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present application provides a gene encoding a G protein-coupled receptor termed nGPCR-14; constructs and recombinant host cells incorporating the genes; the nGPCR-14 polypeptides encoded by the gene; antibodies to the nGPCR-x polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-2067; constructs and recombinant host cells incorporating the genes; the nGPCR-2067 polypeptides encoded by the gene; antibodies to the nGPCR-2067 polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed Con-218; constructs and recombinant host cells incorporating the genes; the Con-218 polypeptides encoded by the gene; antibodies to the polypeptides; and methods of making and using all of the foregoing.

Abstract: The present invention provides a gene encoding a G protein-coupled receptor termed nGPCR-2644; constructs and recombinant host cells incorporating the genes; the nGPCR-2644 polypeptides encoded by the gene; antibodies to the nGPCR-2644 polypeptides; and methods of making and using all of the foregoing.

Abstract: Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.

Abstract: The present invention relates to citrate lyase polypeptides and to nucleic acid molecules coding for such polypeptides. Citrate lyase is transcriptionally regulated in adipose tissue, suggesting involvement in a novel pathway in energy expenditure, downstream of fatty acid metabolism. This makes CitE an attractive drug target for treating and/or preventing diseases such as obesity. Accordingly, the invention refers to the novel mammalian CitE-polypeptide, as well as homologs and functionally equivalent variants thereof. Further, the invention refers to the nucleic acid sequence encoding the novel protein and to vectors for expressing the protein in various organisms. The invention also refers to methods for expressing the protein in said organisms and for purifying the protein upon overexpression. Moreover, the invention refers to a methods wherein CitE is used for screening for substances that affect the activity of CitE.